The estimated Net Worth of Richard C Williams is at least 363 千$ dollars as of 24 May 2019. Mr. Williams owns over 50,000 units of Adamis Pharmaceuticals Corp stock worth over 184,737$ and over the last 10 years he sold ADMP stock worth over 0$. In addition, he makes 178,529$ as Independent Chairman of the Board、 Consultant at Adamis Pharmaceuticals Corp.
Sign up
Mr. Williams ADMP stock SEC Form 4 insiders trading
Richard has made over 2 trades of the Adamis Pharmaceuticals Corp stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 50,000 units of ADMP stock worth 78,500$ on 24 May 2019.
The largest trade he's ever made was buying 50,000 units of Adamis Pharmaceuticals Corp stock on 24 May 2019 worth over 78,500$. On average, Richard trades about 5,980 units every 138 days since 2014. As of 24 May 2019 he still owns at least 239,918 units of Adamis Pharmaceuticals Corp stock.
You can see the complete history of Mr. Williams stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Richard Williams biography
Richard C. Williams serves as Independent Chairman of the Board, Consultant of the Company. Mr. Williams became a director and Chairman of the Board in August 2014. Since 1989, Mr. Williams has served as the founder and President of Conner-Thoele Limited, a consulting and financial advisory firm specializing in the healthcare industry and pharmaceutical segment. Prior to founding Conner-Thoele Limited in 1989, Mr. Williams served in a number of progressively responsible operational and financial management positions with multinational firms. These firms included American Hospital Supply Corporation, UNC Resources, Abbott Laboratories, Field Enterprises and Erbamont NV. Mr. Williams has served as a director and Vice Chairman of Strategic Planning for King Pharmaceuticals. Prior to King, he served as Chairman and a director of Medco Research before Medco was acquired by King Pharmaceuticals. Mr. Williams has also served as a director of several other public and private companies, several as Chairman, including Ista Pharmaceuticals, Vysis Pharmaceuticals, Immunemedics, EP Medical and the Company. Mr. Williams served as a director of the Company from November 2003 to April 2009, and was Chairman of the Company from November 2003 to April 2009, when the Company merged with Old Adamis (which was then named Adamis Pharmaceuticals Corporation) and changed its corporate name to Adamis Pharmaceuticals Corporation. Following the merger, Mr. Williams served as Chairman of the Company until June 2009. He served as a director of Ista Pharmaceuticals from December 2002 to June 2012 and as Chairman of the Board from July 2004 to June 2012, when Ista was acquired. He was a member of the Listed Company Advisory Committee of New York Stock Exchange. Mr. Williams received a Bachelor of Arts degree in Economics from DePauw University and a Masters of Business Administration from the Wharton School of Finance.
What is the salary of Richard Williams?
As the Independent Chairman of the Board、 Consultant of Adamis Pharmaceuticals Corp, the total compensation of Richard Williams at Adamis Pharmaceuticals Corp is 178,529$. There are 6 executives at Adamis Pharmaceuticals Corp getting paid more, with Dennis Carlo having the highest compensation of 1,770,310$.
How old is Richard Williams?
Richard Williams is 76, he's been the Independent Chairman of the Board、 Consultant of Adamis Pharmaceuticals Corp since 2014. There are 2 older and 10 younger executives at Adamis Pharmaceuticals Corp. The oldest executive at Adamis Pharmaceuticals Corp is Dr. Dennis J. Carlo, 78, who is the Pres, CEO & Director.
What's Richard Williams's mailing address?
Richard's mailing address filed with the SEC is C/O ADAMIS PHARMACEUTICALS CORPORATION, 11682 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130.
Insiders trading at Adamis Pharmaceuticals Corp
Over the last 14 years, insiders at Adamis Pharmaceuticals Corp have traded over 2,051,720$ worth of Adamis Pharmaceuticals Corp stock and bought 87,550 units worth 188,843$ . The most active insiders traders include Ahmed Shayan Fazlur Eses Ho...、Dennis J Phd Carlo、David J. Marguglio. On average, Adamis Pharmaceuticals Corp executives and independent directors trade stock every 34 days with the average trade being worth of 12,919$. The most recent stock trade was executed by Dennis J Phd Carlo on 25 May 2022, trading 250,000 units of ADMP stock currently worth 192,500$.
What does Adamis Pharmaceuticals Corp do?
adamis pharmaceuticals corporation (nasdaq: admp) is a specialty biopharmaceuticals company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergies, oncology and immunology. its specialty pharmaceutical division currently has four products in its pipeline including the epinephrine injection pre-filled syringe (pfs) for use in the emergency treatment of anaphylaxis, apc-1000 and apc-5000 (dry powder inhaler) for the treatment of asthma and chronic obstructive pulmonary disease (copd), and apc-3000, a hydrofluoroalkane (hfa) inhaled nasal steroid product for the treatment of allergic rhinitis. this division’s focus is to create low cost therapeutic alternatives to existing treatments in large markets. adamis will pursue 505(b)(2) regulatory approval filings in order to minimize costs and shorten the time to market in this division. within its biotechnology division, the company has four products under development include telob-vax, a
What does Adamis Pharmaceuticals Corp's logo look like?
Complete history of Mr. Williams stock trades at Adamis Pharmaceuticals Corp
Adamis Pharmaceuticals Corp executives and stock owners
Adamis Pharmaceuticals Corp executives and other stock owners filed with the SEC include:
-
Dennis Carlo,
President, Chief Executive Officer, Director -
Ronald Moss,
Chief Medical Officer -
Robert Hopkins,
Chief Financial Officer, Senior Vice President - Finance -
Dr. Dennis J. Carlo,
Pres, CEO & Director -
David Marguglio,
Senior Vice President, Chief Business Officer and Director -
Karen Daniels,
Vice President - Operations -
Richard Williams,
Independent Chairman of the Board, Consultant -
David J. Marguglio,
Sr. VP, Chief Bus. Officer & Director -
Mark Flather,
Director, Investor Relations and Corporate Communications -
Roshawn Blunt,
Independent Director, Consultant -
Howard Birndorf,
Independent Director, Consultant -
Robert B. Rothermel,
Consultant -
Eddie Wabern Glover,
Chief Exec. Officer of US Compounding Inc -
Jennifer C. Suski,
Sr. Director of Marketing -
Karen K. Daniels,
VP of Operations -
David C. Benedicto,
Chief Financial Officer -
Thomas Moll,
Vice President of Research -
William C Denby,
Director -
Eddie Wabern Glover,
CEO of US Compounding, Inc. -
Robert B Rothermel,
Director -
Ahmed Shayan Fazlur Eses Ho...,
-
Tina Susan Nova,
Director -
Kenneth M Cohen,
Director -
Craig A Johnson,
Director -
Meera J. Desai,
Director -
David C. Benedicto,
Chief Financial Officer -
Vickie S Reed,
Director -
Ebrahim Versi,
CEO -
Jannine Versi,
Director